Abstract Activating transcription factor 2 (ATF2) is a member of the cAMP response element
binding protein family that heterodimerizes and activates other transcription factors involved …

Currently, the overall incidence and risk of infections with epidermal growth factor receptor
(EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients …

Abstract Background/Aims: The epidermal growth factor receptor-tyrosine kinase inhibitor
gefitinib is effective against several malignancies and is mainly utilized in the treatment of …

Introduction There are increasing concerns about the negative impacts of chemotherapy
near the end of life (EOL). There is discrepancy among different countries about its use, and …

Background: Erlotinib is a validated drug “for the treatment of patients affected by advanced
unresectable non small cell lung cancer (NSCLC) with EGFR mutations”. We want to focus …

Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Non-
small-cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases emerged targeted …

Abstract A series of novel 2, 4-diarylaminopyrimidine derivatives of AZD9291 were
discovered as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) …

Tyrosine kinase inhibitors (TKIs) telah direkomendasikan oleh National Comprehensive
Cancer Network (NCCN) sebagai terapi lini pertama pada pasien non-small cell lung cancer …

Cancer is the second leading cause of death globally. Matching proper treatment and
dosage is crucial for a positive outcome. Any given drug may affect patients with similar …

Background. Excision tissue biopsy, while central to cancer treatment and precision
medicine, presents risks to the patient and does not provide a su ciently broad and faithful …